The off-the-shelf chimeric antigen receptor T-cell therapy P-BCMA-ALLO1 was shown to be safe and elicited strong anti-tumor ...

Antengene’s Xpovio approved for reimbursement in Taiwan to treat adult patients with relapsed/refractory multiple myeloma: Shanghai Friday, February 14, 2025, 16:00 Hrs [IST] An ...

IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies and biologics, today announced ...

This review summarizes the mechanisms of action and clinical activity of IMiDs in MM. Multiple myeloma (MM) is a malignant plasma cell disorder accounting for approximately 10% of all hematologic ...

Paris: Sanofi has announced that the National Medical Products Administration (NMPA) in China has approved Sarclisa, in combination with a standard-of-care regimen, bortezomib, lenalidomide, ...

When blood cancer cells break through the bone and multiply, tumor cells become dangerously diverse and the immune response ...

In summary, MYC activation may be a common transforming event in myeloma. This activation may be mediated by multiple mechanisms, and tumors with MYC activation have a more aggressive course ...

CHICAGO, IL / ACCESS Newswire / February 10, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in ...

T-cell therapy represents a groundbreaking advancement in the field of immuno-oncology. This innovative treatment involves ...

Q4 2024 Earnings Call Transcript February 6, 2025 Bristol-Myers Squibb Company beats earnings expectations. Reported EPS is ...

Operator Welcome to the Bristol Myers Squibb fourth quarter 2024 earnings conference call. [Operator instructions] Please note this event is being recorded. I would now like to turn the conference ...